Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary vascular condition characterized
by the development of abnormal connections between arteries and veins throughout the body,
called vascular malformations. These abnormal blood vessels are referred to as arteriovenous
malformations (AVM) if they are large and telangiectasias if they are small. Telangiectasias
develop due to irregular growth of blood vessels.
Anti-angiogenic therapy, such as the drug Apo-Timop, curbs the growth of new blood vessels.
Apo-Timop is included in a class of medications called beta-blockers. Anti-angiogenic
therapies exert their beneficial effects in a number of ways: by disabling the agents that
activate and promote cell growth, or by directly blocking the growing blood vessel cells.
The investigators think that anti-angiogenic therapy may lead to the shrinking of
telangiectasia in people with HHT. The investigators hope that this study will provide us
with proof of this concept and might lead to the development and study of anti-angiogenic
therapies to help improve the lives of individuals with vascular malformations.
Phase:
N/A
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Ryerson University Sunnybrook Health Sciences Centre The Hospital for Sick Children University of California, San Francisco University of Toronto